Table 2. Immune-mediated Treatment Emergent Adverse Events (imAE) at Least Possibly Related to Pembrolizumab.

Toxicity Grade	CD4+ 50-199 cells/μL (n=11) n (%)	CD4+ 200-350 cells/μL (n=6) n (%)	CD4+ >350 cells/μL (n=15) n (%)	All participants (n=32) n (%)
Patients with ≥1 imAE
Any grade	1 (9.1)	3 (50)	6 (40)	10 (31.3)
Grade 1	0	0	1 (6.7)	1 (3.1)
Grade 2	1 (9.1)	2 (33.3)	2 (13.3)	5 (15.6)
Grade 3	0	1 (16.7)	3 (20)	4 (12.5)
Anemia
Grade 3	0	0	1 (6.7)	1 (3.1)
Colitis
Grade 3	0	0	1 (6.7)	1 (3.1)
Hypothyroidism
Grade 2	0	1 (16.7)	1 (6.7)	2 (6.3)
Cytomegalovirus infection reactivation
Grade 3	0	1 (16.7)	0	1 (3.1)
Mycobacterium avium complex
Grade 3	0	1 (16.7)	0	1 (3.1)
Blood bilirubin increased
Grade 2	1 (9.1)	0	1 (6.7)	2 (6.3)
Arthralgia
Grade 2	0	0	1 (6.7)	1 (3.1)
Pain in extremity
Grade 1	0	0	1 (6.7)	1 (3.1)
Grade 2	0	0	1 (6.7)	1 (3.1)
Pneumonitis
Grade 2	0	1 (16.7)	0	1 (3.1)
Grade 3	0	0	1 (6.7)	1 (3.1)
Maculo-papular rash
Grade 3	0	0	1 (6.7)	1 (3.1)
Skin hypopigmentation
Grade 1	0	0	1 (6.7)	1 (3.1)

imAE indicates immune-mediated treatment-emergent adverse event